A. von Rohr

708 total citations
25 papers, 530 citations indexed

About

A. von Rohr is a scholar working on Oncology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, A. von Rohr has authored 25 papers receiving a total of 530 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Genetics and 9 papers in Pathology and Forensic Medicine. Recurrent topics in A. von Rohr's work include Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (9 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). A. von Rohr is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (9 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). A. von Rohr collaborates with scholars based in Switzerland, United Kingdom and Germany. A. von Rohr's co-authors include A Tobler, Daniel Betticher, Martin F. Fey, U Hess, Bettina Borisch, Andrew Ziemiecki, MF Fey, M Oestreicher, Sabina Liechti‐Gallati and S.‐F. Hsu Schmitz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

A. von Rohr

25 papers receiving 505 citations

Peers

A. von Rohr

GENET

PFM

ONCOL

HEMAT

IMMUN

Hai‐Rong Qiu China

M. P. A. Lyttelton United Kingdom

Gillian Turner United Kingdom

Takuya Komeno Japan

Lucia Casarino Italy

Michiaki Koike Japan

Cécile Tomowiak France

JP Greer United States

Paolo Fiumara Italy

Hideaki Mizoguchi Japan

Hai‐Rong Qiu China

A. von Rohr

211 ×0.8

GENET

135 ×0.7

PFM

150 ×0.9

ONCOL

216 ×1.4

HEMAT

104 ×0.9

IMMUN

Citations per year, relative to A. von Rohr A. von Rohr (= 1×) peers Hai‐Rong Qiu

Countries citing papers authored by A. von Rohr

Since Specialization

Citations

This map shows the geographic impact of A. von Rohr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. von Rohr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. von Rohr more than expected).

Fields of papers citing papers by A. von Rohr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. von Rohr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. von Rohr. The network helps show where A. von Rohr may publish in the future.

Co-authorship network of co-authors of A. von Rohr

This figure shows the co-authorship network connecting the top 25 collaborators of A. von Rohr. A scholar is included among the top collaborators of A. von Rohr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. von Rohr. A. von Rohr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Emmerich, B., et al.. (2010). Bortezomib Retreatment in Relapsed Multiple Myeloma – Results from a Retrospective Multicentre Survey in Germany and Switzerland. Oncology. 79(3-4). 247–254. 34 indexed citations

Popescu, Răzvan, et al.. (2010). Rapid Anaemia Control with Epoetin: Results of a Swiss Survey on Treatment of Chemotherapy-Induced Anaemia. Acta Haematologica. 123(2). 129–134. 1 indexed citations

Emmerich, B., A. von Rohr, Monika Engelhardt, et al.. (2008). Bortezomib Retreatment in Relapsed Multiple Myeloma (MM): Results from a Binational, Multicenter Retrospective Survey. Blood. 112(11). 2775–2775. 6 indexed citations

Salzberg, Marc, Geoffrey Delmore, A. von Rohr, et al.. (2007). Pegylated Liposomal Doxorubicin (Caelyx®) in Metastatic Breast Cancer: A Community-Based Observation Study. Oncology. 72(3-4). 147–151. 11 indexed citations

Betticher, Daniel, Giovanni Martinelli, John Radford, et al.. (2006). Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL). Annals of Oncology. 17(10). 1546–1552. 34 indexed citations

Rohr, A. von, S.‐F. Hsu Schmitz, André Tichelli, et al.. (2002). Treatment of hairy cell leukemia with cladribine(2-chlorodeoxyadenosine) by subcutaneous bolus injection:a phase II study. Annals of Oncology. 13(10). 1641–1649. 37 indexed citations

Ḧopfner, M., et al.. (2001). Yersinia enterocolitica Infection with Multiple Liver Abscesses Uncovering a Primary Hemochromatosis. Scandinavian Journal of Gastroenterology. 36(2). 220–224. 33 indexed citations

Betticher, Daniel, Daniel Ratschiller, S.‐F. Hsu Schmitz, et al.. (1998). Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Annals of Oncology. 9(7). 721–726. 24 indexed citations

Betticher, Daniel, A. von Rohr, Daniel Ratschiller, et al.. (1998). Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 16(3). 850–858. 23 indexed citations

10.

Betticher, Daniel, S.‐F. Hsu Schmitz, Daniel Ratschiller, et al.. (1997). Cladribine (2‐CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. British Journal of Haematology. 99(2). 358–363. 37 indexed citations

11.

Rohr, A. von, et al.. (1996). Intensive induction and consolidation chemotherapy in a young woman with acute myeloid leukemia and severe chronic renal failure. Annals of Hematology. 72(5). 327–328. 1 indexed citations

12.

Borisch, Bettina, et al.. (1996). Clonal analysis of a B-cell lymphoma with recurrent spontaneous remissions and evolution into chronic lymphocytic leukaemia. Annals of Oncology. 7(9). 953–960. 5 indexed citations

13.

Betticher, Daniel, Emanuele Zucca, A. von Rohr, et al.. (1996). 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III–IV non-Hodgkin's lymphoma. Annals of Oncology. 7(8). 793–799. 17 indexed citations

14.

Betticher, Daniel, Martin F. Fey, A. von Rohr, et al.. (1994). High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Annals of Oncology. 5(1). 57–64. 65 indexed citations

15.

Fey, MF, Sabina Liechti‐Gallati, A. von Rohr, et al.. (1994). Clonality and X-inactivation patterns in hematopoietic cell populations detected by the highly informative M27 beta DNA probe [see comments]. Blood. 83(4). 931–938. 111 indexed citations

16.

Rohr, A. von, et al.. (1993). Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. British Journal of Cancer. 67(1). 163–171. 20 indexed citations

17.

Rohr, A. von & Nicholas Thatcher. (1992). Clinical applications of interleukin-2. PubMed. 4(3). 229–246. 3 indexed citations

18.

Cerny, T., Martin F. Fey, Rolf Oppliger, et al.. (1992). Prevalence of the rhesus‐negative phenotype in caucasian patients with small‐cell lung cancer (SCLC). International Journal of Cancer. 52(3). 504–506. 18 indexed citations

19.

Schanker, Howard M., Gary S. Rachelefsky, Sarah Siegel, et al.. (1992). Immediate and delayed type hypersensitivity to malathion.. PubMed. 69(6). 526–8. 7 indexed citations

20.

Rohr, A. von, et al.. (1991). Phase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer. European Journal of Cancer and Clinical Oncology. 27(9). 1106–1108. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact